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address basic and other health-related self-care needs. The target population
included people ages 18 and older, English speaking, living in 1 of 16 ZIP codes
on Chicago’s south and west sides (106mi2) who received care at ≥1 of 28
CommunityRx partner sites and had a diagnosis of asthma or COPD. Between
December 2015 and December 2016, information about pulmonary research
participation opportunities was included on the HealtheRxs of eligible patients
contemporaneously with usual registry recruitment methods. Usual methods,
used since 2010 by the PRR group, included public advertisements requiring the
patient to call the research team for more information and education of eligible
patients identified during routine clinical care with a Pulmonary/Critical Care
clinician or when enrolling in a pulmonary clinical trial. We hypothesized that,
compared with usual recruitment practices, the HealtheRx recruitment
strategy would increase the rate and decrease the per subject cost of patient
recruitment to a prospective registry. Total annual recruitment costs for each
method were calculated and divided by the number of consented PRR enrollees
per method. RESULTS/ANTICIPATED RESULTS: BetweenDecember 22, 2015
and December 15, 2016 13,437 HealtheRxs (8762 for asthma, 3842 for COPD,
and 833 for both asthma and COPD) were generated with the recruitment
advertisement. In total, 41 patients responded to the ad and participated in the
phone survey. In which 15 (36.5%) participants self-reported a diagnosis of
asthma only (65% of all HealtheRxs with advertisement were for asthma only),
9 (22%) reported a diagnosis of COPD only (28.5% of all HealtheRxs with
advertisement were for COPD only), and 17 (41.5%) reported diagnoses of
both asthma and COPD (6.2% of all HealtheRxs with advertisement were for
asthma and COPD). Most participants were female (n= 28), non-Hispanic black
(n= 37), and not employed (n= 39). The median age was 57. The majority
(n= 31) had never participated in health or medical research and was not aware
of current opportunities to participate in research (n= 25). All 41 participants
expressed interest in joining PRR and were mailed a blank PRR consent form
and a prepaid return envelope with their incentive check for the telephone
survey. To date, 5 participants returned a signed consent form via mail and were
enrolled in PRR. During the same period, 4 patients enrolled in PRR via usual
recruitment methods. The cost per subject to enroll in PRR was $364.40 using
the HealtheRx recruitment and $4590 using usual practice. DISCUSSION/
SIGNIFICANCE OF IMPACT: NIH has called for innovation in research
recruitment methodologies to increase enrollment especially of people who are
under-represented in clinical trials research. This study demonstrates the
feasibility and efficiency of using an EMR-integrated recruitment method to
enroll people of under-represented minority groups to a research registry.
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OBJECTIVES/SPECIFIC AIMS: Prostate cancer is the second most common
cancer in the world for men. For reasons still unclear, aggressive PCa
disproportionately affects males of African ancestry (MoAA). Incidence and
mortality rates are highest in MoAA as they have consistently shown a 2.3–3.0-
fold higher risk of mortality compared with Caucasian men. This aggressiveness
of PCa may be due to specific biological factors. Studies have established that
microRNAs (miRNAs), essential in post-transcriptional gene regulation, are
dysregulated in PCa. miR-1207-3p is encoded at the PVT1 gene locus, which is
located downstream of MYC on the 8q24 PCa susceptibility locus. The
chromosomal region 8q24 is associated with aggressive PCa. Yet miR-1207-3p
in PCa in MoAA has never been investigated. Moreover, studies have shown
that PVT1/MYC co-operation is a fundamental feature in all cancers with 8q24
amplification and 98% of the 8q24 amplicons contained concurrent amplifica-
tion of the MYC and PVT1 loci. Moreover, MYC has been linked to PCa
aggressiveness, and has been reported to be downstream of androgen receptor
(AR) in some PCa. However, the mechanisms regulating c-MYC have never
been studied in MoAA. We have recently demonstrated that miR-1207-3p has
prognostic value in PCa, and directly binds to the 3′ UTR of Fibronectin type III
domain containing 1 (FNDC1) to regulate a novel FNDC1/fibronectin (FN1)/
AR pathway upregulated in metastatic PCa. However, the relevance of this
novel and clinically significant miR-1207-3p molecular pathway in PCa in MoAA
is unknown. Therefore, we hypothesized that miRNA 1207-3p, encoded at the
8q24 PCa susceptibility locus, is a PCa biomarker with clinical applications in
MoAA. Our specific aim was to assess the clinical relevance of miR-1207-3p,
FNDC1, FN1, AR, and MYC expression in aggressive PCa in a cohort of West
African Black males. METHODS/STUDY POPULATION: Consequently, we
aimed to determine the expression profile of miRNA-1207-3p, FNDC1, FN1,
AR, and MYC in histologically confirmed normal prostate (n= 24), benign
prostate (n= 44) and malignant prostate tissue (n= 29) from prostatectomy or
transrectal ultrasound-guided biopsies in patients recruited at the University
College Hospital, Ibadan, Nigeria, a sub-Saharan Black African population. In
total, 17 patients had tumor tissues with Gleason score ≥8. Tissues were
collected in compliance with Institutional Ethics Board approved protocols.
RNA extraction, cDNA synthesis, and quantitative-PCR were performed to
analyze mRNA expression of miRNA-1207-3p, FNDC1, FN1, AR, and MYC.
Statistical analysis were performed using SPSS software. All data were analyzed
by the 1-way ANOVA test. Tukey post-hoc test was performed to determine
the differences in mean expression between normal and tumor prostate tissues.
p< 0.05 were considered significant. RESULTS/ANTICIPATED RESULTS: We
discovered that miR-1207-3p is significantly underexpressed in prostate tumor
tissues [0.09± 0.02, 95%CI (0.04, 0.136), p= 0.000] in comparison with normal
prostate tissue in MoAA [0.92± 0.15, 95% CI (0.60, 1.244), p= 0.000]. This is
the first description of miR-1207-3p differential expression in human clinical
PCa in MoAA. In contrast, FNDC1 was significantly overexpressed in prostate
tumor tissues [21.93± 8.21, 95% CI (4.97, 38.89), p= 0.003] in comparison
with normal prostate tissues in MoAA [1.57± 0.45, 95% CI (0.625, 2.51),
p= 0.003]. The same positive correlation with advanced disease held true for
FN1 [tumor: 13.66± 3.53, 95% CI (6.38, 20.93), p= 0.000; normal:
1.07± 0.235, 95% CI (0.58, 1.56), p= 0.000], AR [tumor: 20.49± 6.74, 95%
CI (6.50, 34.48), p= 0.000; normal: 0.94± 0.20, 95% CI (0.52, 1.36), p= 0.000],
and c-MYC [tumor: 33.93± 8.43, 95% CI (16.53, 51.33), p= 0.000; normal:
1.94± 0.36, 95% CI (1.18, 2.70)]. The significantly increased mean expression
for FNDC1, FN1, AR, and c-MYC in prostate tumor tissues in comparison with
normal prostate tissues indicate that their overexpression is associated with
increased risk of cancer progression in MoAA. DISCUSSION/SIGNIFICANCE
OF IMPACT: These results show that the underexpression of miR-1207-3p and
the overexpression of FNDC1, FN1, AR and MYC is associated with aggressive
PCa in MoAA. miR-1207-3p, and it molecular target FNDC1, may be useful
biomarkers for prognostication of PCa in MoAA.
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OBJECTIVES/SPECIFIC AIMS: Recent evidence from resting-state fMRI studies
have shown that brain network connectivity is altered in patients with
neurodegenerative disorders. However, few studies have examined the
complete connectivity patterns of these well-reported RSNs using a whole
brain approach and how they compare between dementias. Here, we used
advanced connectomic approaches to examine the connectivity of RSNs in
Alzheimer disease (AD), Frontotemporal dementia (FTD), and age-matched
control participants. METHODS/STUDY POPULATION: In total, 44 partici-
pants [27 controls (66.4± 7.6 years), 13 AD (68.5.63± 13.9 years), 4 FTD
(59.575± 12.2 years)] from an ongoing study at Indiana University School of
Medicine were used. Resting-state fMRI data was processed using an in-house
pipeline modeled after Power et al. (2014). Images were parcellated into 278
regions of interest (ROI) based on Shen et al. (2013). Connectivity between
each ROI pair was described by Pearson correlation coefficient. Brain regions
were grouped into 7 canonical RSNs as described by Yeo et al. (2015). Pearson
correlation values were then averaged across pairs of ROIs in each network and
averaged across individuals in each group. These values were used to determine
relative expression of FC in each RSN (intranetwork) and create RSN profiles
for each group. RESULTS/ANTICIPATED RESULTS: Our findings support
previous literature which shows that limbic networks are disrupted in FTLD
participants compared with AD and age-matched controls. In addition,
interactions between different RSNs was also examined and a significant
difference between controls and AD subjects was found between FP and DMN
RSNs. Similarly, previous literature has reported a disruption between
executive (frontoparietal) network and default mode network in AD compared
with controls. DISCUSSION/SIGNIFICANCE OF IMPACT: Our approach
allows us to create profiles that could help compare intranetwork
FC in different neurodegenerative diseases. Future work with expanded
samples will help us to draw more substantial conclusions regarding differences,
if any, in the connectivity patterns between RSNs in various neurodegenerative
diseases.
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